Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Cumberland Pharmaceuticals Adds Vibativ®


 
A.J. Kazimi

Cumberland Pharmaceuticals recently announced the addition of Vibativ® (telavancin) to its growing product lineup. The Nashville-headquartered specialty pharmaceutical company entered into a definitive agreement to acquire Vibativ from Theravance Biopharma in the fourth quarter of 2018.

The FDA-approved injectable antibiotic is used for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

"Vibativ is a lifesaving product for certain difficult to treat infections, and we are honored to be selected to acquire and transition the brand to our existing hospital acute care infrastructure," said Cumberland Pharmaceuticals CEO A.J. Kazimi, "Our immediate plan for Vibativ is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion and medical initiatives to help ensure that the product is available to the patients who need it. We are very optimistic about the opportunity that Vibativ will offer Cumberland."

The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties of up to 20 percent on future U.S. net product sales. Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Kazimi said Cumberland expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ, as well as its oncology and acute care brands.

 
Share:

Related Articles:


Recent Articles

Hot spots identified for colorectal cancer mortality rates among young women

Read More

ONcology Rounds

Read More

Minority Report

All cancers are not created equally. Recent Vanderbilt research show stomach, lung and appendiceal cancers are on the rise and detected later among certain ethnic groups.

Read More

Rounding on Addiction

Read More

Women and Addiction

Prenatal addiction services needed to bridge the gap in addiction, obstetrics

Read More

State of Recovery

Efforts are underway by TDMHSAS leadership to reach more Tennesseans suffering with addiction through education and recovery initiatives.

Read More

AMA Backs Policy Proposals to Cover More of the Uninsured

CHICAGO -- The American Medical Association (AMA) House of Delegates adopted principles today supporting public policy approaches that have the potential to expand insurance coverage to millions of the uninsured, including those who have lost their coverage during the COVID-19 pandemic.

Read More

Statins to be Studied for Prevention of Dementia, Disability, and Heart Disease

Vanderbilt University Medical Center (VUMC) researchers are enrolling adults age 75 and over to study whether taking atorvastatin, a drug commonly used to lower cholesterol, also called Lipitor®, can help maintain health by preventing dementia, disability, and heart disease.

Read More

Addressing Opioid Usage in the Hospital Setting

Opioid misuse often traces its roots to medically valid pain management intervention. Increased awareness of addiction has led providers to look for effective alternatives. In the hospital setting, recent studies find Caldolor® might be one such option.

Read More

Nashville Health Care Council: 25 Years Old & Growing

This year marks the 25th anniversary of the Nashville Health Care Council, an organization that was founded by the local health care community with the purpose of establishing Nashville as the nation's health care capital.

Read More

Email Print
 
 

 

 


Tags:
Cumberland Pharmaceuticals, Drug-Resistant Infection, Gram-Positive Bacterial Infection, HABP/VABP, Hospital-Aquired and Ventilator-Associated Bacterial Pneumonia, Injectable Antibiotic, MRSA, Telavancin, Vibativ
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: